MARKET

DMTK

DMTK

DermTech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.12
-0.27
-2.18%
Closed 16:00 07/10 EDT
OPEN
12.59
PREV CLOSE
12.39
HIGH
12.59
LOW
11.85
VOLUME
98.98K
TURNOVER
--
52 WEEK HIGH
21.70
52 WEEK LOW
4.520
MARKET CAP
219.45M
P/E (TTM)
-6.7728
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DMTK stock price target is 24.00 with a high estimate of 24.00 and a low estimate of 24.00.

EPS

DMTK News

More
DermTech Announces Inclusion in the Russell 2000 Index
Business Wire · 06/30 13:00
DermTech Announces Inclusion In The Russell 2000 Index
Benzinga · 06/30 12:14
Here's Why We're Not Too Worried About DermTech's (NASDAQ:DMTK) Cash Burn Situation
Simply Wall St. · 06/16 11:40
Here is What Hedge Funds Think About DermTech, Inc. (DMTK)
In this article you are going to find out whether hedge funds think DermTech, Inc. (NASDAQ:DMTK) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been sever
Insider Monkey · 06/10 19:27
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/22 09:26
DermTech PLA Included in Peer Review Article of Novel Molecular Technologies for Melanoma Management with Potential to Address Current Gaps in Diagnostic Accuracy and Prognostication
Business Wire · 05/20 21:30
DermTech EPS misses by $0.07, beats on revenue
DermTech (NASDAQ:DMTK): Q1 GAAP EPS of -$0.53 misses by $0.07. Revenue of $1.56M (+160.0% Y/Y) beats by $0.56M. Press Release
seekingalpha · 05/14 01:26
DermTech Q1 EPS $(0.530) Misses $(0.400) Estimate, Sales $1.557M
DermTech (NASDAQ:DMTK) reported quarterly losses of $(0.530) per share which missed the analyst consensus estimate of $(0.400) by 32.5 percent. The company reported $1.557 million in sales this quarter.
Benzinga · 05/13 20:02

Industry

Medical Equipment, Supplies & Distribution
-0.07%
Healthcare Equipment & Supplies
-0.31%

Hot Stocks

Symbol
Price
%Change

About DMTK

DermTech, Inc. is a molecular dermatology company that focuses on skin cancer. The Company develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The Company provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. It provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. It offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The Company is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. It also offers ResponseTNF product and CytokineEx 17 product.
More

Webull offers kinds of DermTech Inc stock information, including NASDAQ:DMTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DMTK stock methods without spending real money on the virtual paper trading platform.